Adalimumab (Humira™): A brief review for dermatologists

Journal of Dermatological Treatment

Volumn 15, Issue 6, 2004, Pages 348-352

  Scheinfeld, Noah ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b St Luke's Roosevelt Hospital Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; CORTICOSTEROID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ARTHRITIS; BILIARY TRACT CANCER; BLEEDING; BREAST CANCER; CARCINOMA; CARDIOVASCULAR DISEASE; CELLULITIS; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DIVERTICULITIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ERYSIPELAS; ERYTHEMA; GALLBLADDER CANCER; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFLUENZA; INJECTION PAIN; LUPUS ERYTHEMATOSUS; LYMPHOMA; MELANOMA; MONOTHERAPY; MYCOSIS; NEPHROTIC SYNDROME; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; PSORIASIS; PYELONEPHRITIS; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; SINUSITIS; TUBERCULOSIS; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; UTERUS CANCER; REVIEW;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10644245971     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630410017284     Document Type: Short Survey

References (23)

1. http://www.fda.gov/cder/foi/label/2002/adalabb12310-2LB.pdf
2. http://www.emea.eu.int/humandocs/PDFs/EPAR/humira/400803en6.pdf
3. Machold KP, Smolen JS, Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther (2003) 3: 351-60.
4. Sandborn WJ, Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol (2003) 17: 105-17.
5. Adalimumab (Humira) for Rheumatoid Arthritis. Med Lett Drugs Ther (2003) 45: 25-7.
6. Goto D, Sumida T, Adalimumab. Nippon Rinsho (2002) 60: 2384-9.
7. Felson DT, Anderson JJ, Lange ML et al, Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum (1998) 41: 1564-70.
8. Pincus T, Ferraccioli G, Sokka T et al, Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) (2002) 41: 1346-56.
9. Den Broeder AA, Joosten LA, Saxne T et al, Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis (2002) 61: 311-18.
10. Van Putte LBA, Rau R, Breedveld FC, et al. Efficacy at the fully human anti-TNF antibody D2E7 in rheumatoid arthritis [abstract no. 1977]. Arthritis Rheum (1999) 42 (suppl 9): S400 (abstr).
11. Weinblatt ME, Keystone EC, Furst DE et al, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 48: 35-45.
12. Keystone EC, Haraoui B, Bykerk VP, Role of adalimumab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol (2003) 21 (5 suppl 31): S198-9.
13. Furst DE, Schiff MH, Fleischmann RM et al, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol (2003) 30: 2563-71.
14. Chen DM, Gordon K, Leonardi C, Menter A, Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. J Am Acad Dermatol (2004) P2 (poster).
15. Gelfand JM, Berlin J, van Voorhees A, Margolis DJ, Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol (2003) 139: 1425-9.
16. Ekstrom K, Hjalgrim H, Brandt L et al, Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum (2003) 48: 963-70.
17. http://www.upmccancercenters.com/news/reuters/reuters. cfm?article=1305 (accessed July 6, 2004)
18. Ziakas PD, Giannouli S, Tzioufas AG, Voulgarelis M, Lymphoma development in a patient receiving anti-TNF therapy. Haematologica (2003) 88: ECR25.
19. Schiff M, van de Putte LBA, Breedveld FC et al, Rates of infection in adalimumab rheumatoid arthritis clinical trials. Annual European Congress of Rheumatology; 21-23 June 2003; Lisbon (abstr).
20. http://abbott.com/news/releaseonly.cfm?id=683. (accessed July 7, 2004).
21. Briefing document: FDA Arthritis Advisory Committee meeting; Bethesda, MD; 4 March 2003. www.fda. gov/ohrms/dockets/ac/03/slides/3930s1.htm. (accessed November 11, 2004).
22. Kwon HJ, Cote TR, Cuffe MS et al, Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 138: 807-11.
23. Den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF, Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med (2003) 61: 137-41.